{
  "trial_id": "NCT02273180",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, duration of type 1 diabetes mellitus, baseline HbA1c, fasting plasma glucose (FPG), self-measured plasma glucose (SMPG) profiles, insulin dose, body mass index (BMI), presence of anti-insulin antibodies, history of diabetic ketoacidosis, history of diabetic retinopathy, use of insulin glargine, use of Humalog or Novolog/Novo Rapid, prior use of insulin pump, prior use of glucose-lowering treatments other than insulin.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Duration of Diabetes Type 1(T1DM)",
          "duration of type 1 diabetes mellitus"
        ],
        [
          "Randomization Strata of Screening HbA1c",
          "baseline HbA1c"
        ],
        [
          "Body mass index (BMI)",
          "body mass index (BMI)"
        ],
        [
          "Glycated Haemoglobin (HbA1c %)",
          "baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Previous mealtime insulin type",
        "Randomization strata of geographical region",
        "Average Daily Basal Insulin Dose",
        "Average Daily Mealtime Insulin Dose",
        "Average Daily Total Insulin Dose"
      ],
      "remaining_candidate_features": [
        "fasting plasma glucose (FPG)",
        "self-measured plasma glucose (SMPG) profiles",
        "insulin dose",
        "presence of anti-insulin antibodies",
        "history of diabetic ketoacidosis",
        "history of diabetic retinopathy",
        "use of insulin glargine",
        "use of Humalog or Novolog/Novo Rapid",
        "prior use of insulin pump",
        "prior use of glucose-lowering treatments other than insulin."
      ]
    },
    "processed-gen-response": "Age, gender, duration of type 1 diabetes mellitus, baseline HbA1c, fasting plasma glucose (FPG), self-measured plasma glucose (SMPG) profiles, insulin dose, body mass index (BMI), presence of anti-insulin antibodies, history of diabetic ketoacidosis, history of diabetic retinopathy, use of insulin glargine, use of Humalog or Novolog/Novo Rapid, prior use of insulin pump, prior use of glucose-lowering treatments other than insulin."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Fasting Plasma Glucose, Self-measured Plasma Glucose (SMPG) profiles, Insulin Dose, Antibody Status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Randomization strata of geographical region",
          "Region of Enrollment"
        ],
        [
          "Duration of Diabetes Type 1(T1DM)",
          "Duration of Diabetes"
        ],
        [
          "Glycated Haemoglobin (HbA1c %)",
          "Baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Previous mealtime insulin type",
        "Randomization Strata of Screening HbA1c",
        "Body mass index (BMI)",
        "Average Daily Basal Insulin Dose",
        "Average Daily Mealtime Insulin Dose",
        "Average Daily Total Insulin Dose"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Fasting Plasma Glucose",
        "Self-measured Plasma Glucose (SMPG) profiles",
        "Insulin Dose",
        "Antibody Status"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Fasting Plasma Glucose, Self-measured Plasma Glucose (SMPG) profiles, Insulin Dose, Antibody Status"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Region of Enrollment, Diabetes Diagnosis Duration, Baseline HbA1c, Fasting Plasma Glucose, Self-Measured Plasma Glucose, Insulin Dose, BMI, Blood Pressure.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Randomization strata of geographical region",
          "Region of Enrollment"
        ],
        [
          "Duration of Diabetes Type 1(T1DM)",
          "Diabetes Diagnosis Duration"
        ],
        [
          "Randomization Strata of Screening HbA1c",
          "Baseline HbA1c"
        ],
        [
          "Body mass index (BMI)",
          "BMI"
        ]
      ],
      "remaining_reference_features": [
        "Previous mealtime insulin type",
        "Average Daily Basal Insulin Dose",
        "Average Daily Mealtime Insulin Dose",
        "Average Daily Total Insulin Dose",
        "Glycated Haemoglobin (HbA1c %)"
      ],
      "remaining_candidate_features": [
        "Fasting Plasma Glucose",
        "Self-Measured Plasma Glucose",
        "Insulin Dose",
        "Blood Pressure"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Region of Enrollment, Diabetes Diagnosis Duration, Baseline HbA1c, Fasting Plasma Glucose, Self-Measured Plasma Glucose, Insulin Dose, BMI, Blood Pressure."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 1 diabetes mellitus (T1DM), HbA1c at baseline, fasting plasma glucose (FPG) at baseline, self-measured plasma glucose (SMPG) profiles at baseline, insulin dose at baseline, presence of diabetic complications (e.g., retinopathy, nephropathy, neuropathy), history of diabetic ketoacidosis, history of pancreas and/or islet cell transplantation, use of concomitant medications (e.g., antihypertensives, lipid-lowering agents).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Body mass index (BMI)",
          "body mass index (BMI)"
        ],
        [
          "Duration of Diabetes Type 1(T1DM)",
          "duration of type 1 diabetes mellitus (T1DM)"
        ],
        [
          "Glycated Haemoglobin (HbA1c %)",
          "HbA1c at baseline"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Previous mealtime insulin type",
        "Randomization Strata of Screening HbA1c",
        "Randomization strata of geographical region",
        "Average Daily Basal Insulin Dose",
        "Average Daily Mealtime Insulin Dose",
        "Average Daily Total Insulin Dose"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "fasting plasma glucose (FPG) at baseline",
        "self-measured plasma glucose (SMPG) profiles at baseline",
        "insulin dose at baseline",
        "presence of diabetic complications (e.g., retinopathy, nephropathy, neuropathy)",
        "history of diabetic ketoacidosis",
        "history of pancreas and/or islet cell transplantation",
        "use of concomitant medications (e.g., antihypertensives, lipid-lowering agents)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 1 diabetes mellitus (T1DM), HbA1c at baseline, fasting plasma glucose (FPG) at baseline, self-measured plasma glucose (SMPG) profiles at baseline, insulin dose at baseline, presence of diabetic complications (e.g., retinopathy, nephropathy, neuropathy), history of diabetic ketoacidosis, history of pancreas and/or islet cell transplantation, use of concomitant medications (e.g., antihypertensives, lipid-lowering agents)."
  }
}